FLGTFulgent Genetics Inc
$19.53
$0.35
(1.76%)
Closed $19.53
$0.00
(0.00%)
After Hours
EarningsJul 30
Mkt Cap$564.6M
Vol240,552.00
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday...
Business Wire
Fulgent Presents Updated FID-007 Data at ASCO 2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO...
Business Wire
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented...
Business Wire
Fulgent Genetics Q1 Earnings Call Highlights
Fulgent Genetics (NASDAQ:FLGT) reported first-quarter 2026 revenue of $71.1 million as the company worked through a planned decline in testing volumes from its largest customer while integrating the...
MarketBeat
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call
read more...
Benzinga
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Fulgent Genetics (NASDAQ:FLGT) Releases FY 2026 Earnings Guidance
Fulgent Genetics (NASDAQ:FLGT) updated its FY 2026 earnings guidance. The company provided EPS guidance of -1.590--1.590 for the period, compared to the consensus estimate of -1.590. The company also...
MarketBeat
Fulgent Reports First Quarter 2026 Financial Results
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Business Wire
iRhythm Holdings, Inc. (IRTC) Reports Q1 Loss, Tops Revenue Estimates
IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +37.78% and +2.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Fulgent Genetics (FLGT) to Release Earnings on Friday
Fulgent Genetics (NASDAQ:FLGT) will be releasing its Q1 2026 earnings before the market opens on Friday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-1-fulgent-genetics-inc-stock...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest FLGT News
ViewFulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Business Wire
Fulgent Presents Updated FID-007 Data at ASCO 2026
Business Wire
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Business Wire
GOOGL15
24
SMCI19
30
RKLB8
14Advertisement|Remove ads.